Kymera Therapeutics, Inc.
KYMR
$81.21
$1.612.02%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.85% | -7.26% | -16.82% | 7.31% | -13.23% |
| Total Depreciation and Amortization | -5.44% | 3.12% | 1.76% | 3.07% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.97% | 31.40% | 13.55% | 11.17% | -6.64% |
| Change in Net Operating Assets | -83.66% | 2,523.76% | 104.94% | -669.50% | -265.71% |
| Cash from Operations | -146.21% | 54.73% | 24.34% | -28.11% | -23.10% |
| Capital Expenditure | 41.44% | 73.96% | -48.82% | 50.11% | -595.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -67.70% | -487.24% | 23.70% | -29.38% | 144.03% |
| Cash from Investing | -67.62% | -492.03% | 23.46% | -29.10% | 143.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.72% | -9.69% | -37.91% | 5.46% | 54.29% |
| Issuance of Common Stock | 1,797.21% | -83.78% | 45,901.50% | -98.30% | -87.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,684.91% | -83.92% | 95,142.64% | -90.67% | -98.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 209.50% | -190.66% | 912.05% | -417.07% | -77.82% |